Indian pharma market logs sixth straight month of double-digit growth in May

Market grows 12.1%; volume contribution improves as 9 out of 10 key therapies post double-digit growth

We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene

Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships

Alithea Genomics and Revvity expand global access to scalable transcriptomics platforms

Collaboration integrates MERCURIUS DRUG-seq technologies with Revvity’s screening portfolio, enabling scalable transcriptomic profiling for next-generation drug discovery and AI-driven research

India’s bioeconomy grew 20-fold in last 12 years: Dr Jitendra Singh

From a $10 billion bioeconomy to over $190 billion, indigenous CAR-T therapy, and a booming startup ecosystem highlight 12 years of transformation in India’s science and technology landscape

FDA clears Dexcom’s Stelo as first OTC Continuous Glucose Monitor for kids

Expanded indication makes Stelo the first FDA-cleared OTC CGM for children aged two years and older with diabetes or prediabetes

Orionis expands Novartis partnership in potential $1.4 billion molecular glue drug feal

Lilly’s Jaypirca cuts risk of disease progression or death by 45% in landmark trial

The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor

OM Pharma to unveil major real-world evidence breakthrough on Broncho-Vaxom at EAACI

The company will unveil preliminary findings showing that Broncho-Vaxom was associated with a 28–38% reduction in respiratory tract infection rates at 12 months

T-CURX gets Swissmedic nod for first human trial of non-viral CAR-T therapy

Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform

Dr Reddy’s launches first-to-market generic Bosutinib in US oncology push

Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing